Jeanne Schilder

  • 2425 Citations
  • 22 h-Index
19972019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Jeanne Schilder is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

TRINOVA-3/ENGOT-ov2/GOG-3001 investigators, Jun 2019, In : The lancet oncology. 20, 6, p. 862-876 15 p.

Research output: Contribution to journalArticle

  • 5 Scopus citations

    Cell origins of high-grade serous ovarian cancer

    Kim, J., Park, E. Y., Kim, O., Schilder, J. M., Coffey, D. M., Cho, C. H. & Bast, R. C., Nov 12 2018, In : Cancers. 10, 11, 433.

    Research output: Contribution to journalReview article

  • 27 Scopus citations

    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

    Tew, W. P., Sill, M. W., Walker, J. L., Secord, A. A., Bonebrake, A. J., Schilder, J. M., Stuckey, A., Rice, L., Tewari, K. S. & Aghajanian, C. A., Nov 2018, In : Gynecologic oncology. 151, 2, p. 257-263 7 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations

    Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

    Monk, B. J., Sill, M. W., Walker, J. L., Darus, C. J., Sutton, G., Tewari, K. S., Martin, L. P., Schilder, J. M., Coleman, R. L., Balkissoon, J. & Aghajanian, C., Jul 1 2016, In : Journal of Clinical Oncology. 34, 19, p. 2279-2286 8 p.

    Research output: Contribution to journalArticle

  • 34 Scopus citations

    A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

    Bender, D., Sill, M. W., Lankes, H. A., Reyes, H. D., Darus, C. J., Delmore, J. E., Rotmensch, J., Gray, H. J., Mannel, R. S., Schilder, J. M., Hunter, M. I., McCourt, C. K., Samuelson, M. I. & Leslie, K. K., Sep 1 2015, In : Gynecologic oncology. 138, 3, p. 507-512 6 p.

    Research output: Contribution to journalArticle

  • 28 Scopus citations